NCT06439355 · RECRUITING

Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis

This study measures how the brain responds to taste in healthy volunteers, people with early Parkinson's disease, and people with early Lewy body disease. Researchers use taste-evoked brain signals, plus blood tests, motor, memory and nutrition checks. It is not a treatment trial. It is an observational look at how taste processing may differ between these conditions.

Eligibility criteria

Inclusion Criteria:
Healthy volunteers:
* Person who has given written consent
* Adult
* Enrolled in the national register of healthy volunteers
* Fasting > 2 hours before PEG measurement
* Body Mass Index (BMI) \< 30 kg/m².
* No cognitive complaints and normal neurological assessment
Patients with idiopathic Parkinson's disease:
* Person who has given written consent
* Adult
* Fasting > 2 hours before PEG measurement
* Body Mass Index (BMI) \< 30 kg/m².
* Diagnostic criteria for established or probable IPD
Patients with Lewy body disease:
* Person who has given written consent
* Adult
* Fasting > 2 hours prior to PEG measurement
* Body Mass Index (BMI) \< 30 kg/m².
* Diagnostic criteria for probable or possible LBD
Exclusion Criteria:
* Non-affiliated to national health insurance
* Person under legal protection (curatorship, guardianship)
* Person subject to a court order
* Pregnant, parturient or breast-feeding women
* Major unable to give consent
* MMSE score \< 15 and/or MoCA \< 10
* Known infection with COVID-19 in the 6 months prior to inclusion
* Active smoker (> 4 cigarettes per day on a regular basis)
* Subject with pacemaker (contraindication for bioelectrical impedancemetry)
* Diabetic (type 1 or type 2)
* Taking medication (in progress at the time of the study) that interferes with gustation

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-10-07

View full record on ClinicalTrials.gov

All APOE4 clinical trials